Strategies for Addressing Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations From the Expert Consensus Guidelines, Journal of Psychiatric Practice, vol.16, issue.5, pp.306-324, 2010. ,
DOI : 10.1097/01.pra.0000388626.98662.a0
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia, Schizophrenia Research, vol.131, issue.1-3, pp.127-132, 2011. ,
DOI : 10.1016/j.schres.2011.04.028
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia, The Journal of Clinical Psychiatry, vol.63, issue.10, pp.892-909, 2002. ,
DOI : 10.4088/JCP.v63n1007
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, vol.70, pp.1-46, 2009. ,
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia, The British Journal of Psychiatry, vol.179, issue.4, pp.290-299, 2001. ,
DOI : 10.1192/bjp.179.4.290
Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials, Schizophrenia Bulletin, vol.40, issue.1, 2013. ,
DOI : 10.1093/schbul/sbs150
Oral versus depot antipsychotic drugs for schizophrenia???A critical systematic review and meta-analysis of randomised long-term trials, Schizophrenia Research, vol.127, issue.1-3, pp.83-92, 2011. ,
DOI : 10.1016/j.schres.2010.11.020
Core interventions in the treatment and management of schizophrenia in primary and secondary care (update), 20704054. ,
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, vol.36, issue.1, pp.71-93, 2010. ,
DOI : 10.1093/schbul/sbp116
Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms, Schizophrenia Research, vol.134, issue.2-3, pp.219-225, 2012. ,
DOI : 10.1016/j.schres.2011.11.021
Antipsychotic long-acting injections: prescribing practice in the UK, The British Journal of Psychiatry, vol.195, issue.52, pp.37-42, 2009. ,
DOI : 10.1192/bjp.195.52.s37
Why aren't depot antipsychotics prescribed more oftenandwhatcanbedoneaboutit?Adv Psychiatr Treat, pp.203-213, 2011. ,
DOI : 10.1192/apt.11.3.203
Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists, British Journal of Clinical Pharmacology, vol.56, issue.1, pp.80-86, 2000. ,
DOI : 10.1046/j.1365-2125.2000.00108.x
Attitudes of Psychiatrists Toward Antipsychotic Depot Medication, The Journal of Clinical Psychiatry, vol.67, issue.12, pp.1948-1953, 2006. ,
DOI : 10.4088/JCP.v67n1216
Guide d'analyse de la littérature et gradation des recommandations ,
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009. ,
DOI : 10.1016/S0140-6736(08)61764-X
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia, American Journal of Psychiatry, vol.166, issue.2, pp.152-163, 2009. ,
DOI : 10.1176/appi.ajp.2008.08030368
Elaboration de recommandations de bonne pratique. Méthode " Recommandations par consensus formalisé " . 2011: [http://www.has-sante.fr/portail/upload/docs/application ,
Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?, Comprehensive Psychiatry, vol.54, issue.4, pp.309-320, 2013. ,
DOI : 10.1016/j.comppsych.2012.10.001
Screening and management of bipolar disorders: methodology, Encephale, pp.36-76, 2010. ,
Screening and management of bipolar disorders: results, Encephale, pp.36-86, 2010. ,
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary, Postgrad Med, pp.6-22, 2005. ,
The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients, Postgrad Med, pp.1-86, 2001. ,
Introduction: Methods, Commentary, and Summary, Journal of Psychiatric Practice, vol.11, issue.Supplement 1, pp.5-108, 2005. ,
DOI : 10.1097/00131746-200511001-00002
Medication Treatment of Bipolar Disorder 2000: A Summary of the Expert Consensus Guidelines, Journal of Psychiatric Practice, vol.6, issue.4, pp.197-211, 2000. ,
DOI : 10.1097/00131746-200007000-00004
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary, J Clin Psychiatry, vol.64, pp.5-19, 2003. ,
Second-generation antipsychotic long-acting injections: systematic review, The British Journal of Psychiatry, vol.195, issue.52, pp.29-36, 2009. ,
DOI : 10.1192/bjp.195.52.s29
Whatistheevidencefortheuseof second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?, Nord J Psychiatry, 2013. ,
Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment, European Psychiatry, vol.25, issue.4, pp.220-229, 2010. ,
DOI : 10.1016/j.eurpsy.2009.09.001
Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies, Clinical Therapeutics, vol.30, issue.12, pp.2378-2386, 2008. ,
DOI : 10.1016/j.clinthera.2008.12.020
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection, International Clinical Psychopharmacology, vol.23, issue.6, pp.325-331, 2008. ,
DOI : 10.1097/YIC.0b013e32830c2042
Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.32, issue.5, pp.1231-1235, 2008. ,
DOI : 10.1016/j.pnpbp.2008.03.012
Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa, Patient Preference and Adherence, vol.7, pp.121-132, 2013. ,
DOI : 10.2147/PPA.S37534
Clinicians??? Attitudes Toward the Use of Long-Acting Injectable Antipsychotics, The Journal of Nervous and Mental Disease, vol.201, issue.7, pp.553-559 ,
DOI : 10.1097/NMD.0b013e31829829c4
Identifying the profile of optimal candidates for antipsychotic depot therapy, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.32, issue.8, pp.1987-1993, 2008. ,
DOI : 10.1016/j.pnpbp.2008.09.025
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia, Psychiatric Services, vol.55, issue.8, pp.886-891, 2004. ,
DOI : 10.1176/appi.ps.55.8.886
Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample, Journal of Affective Disorders, vol.127, issue.1-3, pp.77-83, 2010. ,
DOI : 10.1016/j.jad.2010.05.021
Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge, American Journal of Health-System Pharmacy, vol.66, issue.4, pp.358-365, 2009. ,
DOI : 10.2146/ajhp080374
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics, Molecular Psychiatry, vol.361, issue.1, pp.53-66, 2013. ,
DOI : 10.1038/mp.2011.143
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons, Schizophrenia Bulletin, vol.38, issue.1, pp.167-177, 2012. ,
DOI : 10.1093/schbul/sbq042
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, Schizophrenia Research, vol.123, issue.2-3, pp.225-233, 2010. ,
DOI : 10.1016/j.schres.2010.07.012
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS), Schizophrenia Research, vol.134, issue.2-3, pp.187-194, 2012. ,
DOI : 10.1016/j.schres.2011.10.022
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases, BMC Psychiatry, vol.13, issue.suppl 1, p.43, 2010. ,
DOI : 10.7748/ns1999.06.13.39.47.c2623
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, vol.356, issue.51, pp.567-620, 2011. ,
DOI : 10.1097/00004714-200002000-00016
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, The World Journal of Biological Psychiatry, vol.28, issue.2, pp.2-44, 2013. ,
DOI : 10.4088/JCP.09m05284yel
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia, The Journal of Clinical Psychiatry, vol.68, issue.11, pp.1751-1762, 2007. ,
DOI : 10.4088/JCP.v68n1115
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, vol.23, issue.4, pp.346-388, 2009. ,
DOI : 10.1177/0269881109102919
Clinical practice recommendations for bipolar disorder, Acta Psychiatrica Scandinavica, vol.2, issue.s434, pp.27-46, 2009. ,
DOI : 10.1111/j.1600-0447.2009.01383.x
International Consensus Group on Depression Prevention in Bipolar Disorder, The Journal of Clinical Psychiatry, vol.72, issue.10, pp.1295-1310, 2011. ,
DOI : 10.4088/JCP.10123co1c
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013, Bipolar Disorders, vol.131, issue.Suppl. 1, pp.1-44, 2013. ,
DOI : 10.1111/bdi.12025
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder, The World Journal of Biological Psychiatry, vol.16, issue.9, pp.154-219, 2013. ,
DOI : 10.1192/bjp.133.5.429
Guidelines for depot antipsychotic treatment in schizophrenia, European Neuropsychopharmacology Consensus Conference in, pp.55-66, 1998. ,
DOI : 10.1016/S0924-977X(97)00045-X
Clinical guideline recommendations for antipsychotic long-acting injections, The British Journal of Psychiatry, vol.195, issue.52, pp.63-67, 2009. ,
DOI : 10.1192/bjp.195.52.s63
Les antipsychotiques injectables ?? action prolong??e: Avis d'experts de l'Association des m??decins psychiatres du Qu??bec, The Canadian Journal of Psychiatry, vol.364, issue.9, pp.367-376, 2011. ,
DOI : 10.1177/070674371105600608
Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics, J Clin Psychiatry, vol.65, pp.120-131, 2004. ,
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?, European Neuropsychopharmacology, vol.20, issue.4, pp.276-279, 2010. ,
DOI : 10.1016/j.euroneuro.2010.01.001